Enanta Pharmaceuticals Inc. (ENTA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Enanta Pharmaceuticals Inc. (ENTA:NASDAQ), powered by AI.

Current Price
$11.90
P/E Ratio
-3.1
Market Cap
254M
Sector
Healthcare
What is the Enanta Pharmaceuticals Inc. stock price forecast?

Enanta Pharmaceuticals Inc. is currently trading at $11.90. View real-time AI analysis on Alpha Lenz.

What is Enanta Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Enanta Pharmaceuticals Inc. on Alpha Lenz.

What is Enanta Pharmaceuticals Inc.'s P/E ratio?

Enanta Pharmaceuticals Inc.'s P/E ratio is -3.1.

Enanta Pharmaceuticals Inc.

NASDAQ · ENTA
$11.90+0.39(+3.39%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Enanta Pharmaceuticals Inc.'s future dividend policy...
Alpha Chat Insight

Enanta Pharmaceuticals Inc. trades at a P/E of -3.1 (undervalued) with modest ROE of -84.6%.

Ask for details

Company Overview

Enanta Pharmaceuticals Inc. is a biotechnology company dedicated to the discovery and development of small molecule drugs. The primary focus of the company is on creating innovative treatments for viral infections and liver diseases. Enanta has a proven track record in drug discovery, having developed lead candidates for hepatitis C virus (HCV), respiratory syncytial virus (RSV), and non-alcoholic steatohepatitis (NASH). Its strategic collaboration with major pharmaceutical companies has resulted in the successful commercialization of HCV treatments. The company's pipeline is rich with potential therapies targeting significant global health issues, maintaining a critical role in advancing medical breakthroughs. Enanta Pharmaceuticals is headquartered in Watertown, Massachusetts and operates in a highly competitive biotech sector, where it leverages deep expertise in medicinal chemistry and drug development to address unmet medical needs. Enanta's contribution to antiviral therapies reinforces its significance in the fast-evolving field of biotechnology.

CEODr. Jay R. Luly Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees131

Company Statistics

FY 2025

Profile

$253.90MMarket Cap
$65.32MRevenue
0.00Shares Out
131Employees

Margins

N/AGross
-109.18%EBITDA
-130.65%Operating
-127.90%Pre-Tax
-125.36%Net

Valuation

-3.10P/E
3.92P/B
3.89EV/Sales
-3.92EV/EBITDA
-7.89P/FCF

Growth (CAGR)

-8.82%Rev 3Yr
-11.81%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-24.91%ROA
-84.63%ROE
-23.08%ROIC

Financial Health

$32.30MCash & Cash Equivalents
$183.72MNet Debt
333.78%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Enanta Pharmaceuticals Inc. (ticker: ENTA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 131 employees. Market cap is $254M.

The current price is $11.9 with a P/E ratio of -3.1x and P/B of 3.92x.

ROE is -84.63% and operating margin is -130.65%. Annual revenue is $65M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Enanta Pharmaceuticals Inc. (ENTA) Stock Forecast 2026 $11.90 — Price, Financials & Analyst Targets | Alpha Lenz